Sana Biotechnology presents preclinical data for in vivo CAR T cell therapy

Sana Biotechnology (SANA) announced the presentation of preclinical data demonstrating that a surrogate SG293, an in vivo CAR T cell therapy, achieved cell-specific delivery, robust and dose-dependent CAR T cell generation, and deep B cell depletion in non-human primates without the use of lymphodepleting chemotherapy. “SG293 represents a differentiated in vivo CAR T cell approach designed to work without lymphodepletion to deliver potent therapeutic activity and exceptional specificity to minimize off-target effects,” said Dhaval Patel, executive VP, chief scientific officer.